Through a series of in vivo and in vitro experiments, we provide evidence that targeting xCT and YTHDC2 in reactive astrocytes significantly reduces extracellular glutamate and mitigates seizure activity, offering novel therapeutic targets for epilepsy treatment. This evidence concerns the gene YTHDC2 and epilepsy.